A newly published peer-reviewed study in the journal EBioMedicine suggests that tirzepatide — the active ingredient in Mounjaro and Zepbound — may reduce the motivation for cocaine in rodents. The finding adds to a growing body of research exploring whether GLP-1 class medications could one day play a role in addiction treatment.
What the Study Found
Researchers found novel evidence that tirzepatide, which acts on both GLP-1 and GIP receptors, reduced cocaine-seeking motivation in rodents. Tirzepatide's dual-receptor mechanism sets it apart from single-receptor GLP-1 drugs like semaglutide (Ozempic, Wegovy), though the study's headline framed the findings broadly under the "GLP-1 drugs" umbrella given the shared receptor pathway.
GLP-1 receptors are found not only in the pancreas and gut but also in brain regions associated with reward and motivation — which is why scientists have been investigating this class of drugs for potential effects on addictive behaviors.
Why This Matters for Patients
For people currently taking Mounjaro or Zepbound for type 2 diabetes or weight loss, this research is early-stage and does not change how or why these medications are prescribed today. However, the findings are scientifically significant because they suggest the drug's effects on reward pathways may extend beyond food and appetite.
- No human trials yet: This study was conducted in rodents. Results in animals frequently do not translate directly to humans.
- Not a current indication: Tirzepatide is not approved or prescribed for addiction treatment at this time.
- Part of a larger trend: Multiple research teams are investigating GLP-1 drugs for alcohol, nicotine, and opioid use disorders, making this cocaine-focused study a notable addition to that field.
Key takeaway: A peer-reviewed rodent study published in EBioMedicine found tirzepatide reduced cocaine motivation — an intriguing early signal, but human trials are needed before this has any implication for patient care.
The Science Behind the Connection
GLP-1 receptor agonists work in part by influencing dopamine-driven reward circuits in the brain. Because addictive substances like cocaine also hijack these same reward pathways, researchers have theorized that modulating GLP-1 activity could dampen the reinforcing effects of drugs. Tirzepatide's additional action on GIP receptors may amplify these effects, which is what makes this dual-agonist finding particularly noteworthy to the research community.
What to Watch Next
The publication in EBioMedicine is likely to accelerate interest in human clinical trials examining tirzepatide and related drugs in people with substance use disorders. Researchers and addiction medicine specialists will be watching for:
- Replication of these rodent findings in larger preclinical models
- Early-phase human trials examining GLP-1 drugs and cocaine or stimulant use disorder
- Mechanistic studies clarifying whether the GIP receptor component plays a distinct role
Frequently Asked Questions
This research is at an early, preclinical stage and should not influence how you use your current medication. If you have questions about how GLP-1 drugs may interact with your personal health history — including any history of substance use — speak with your prescriber before making any changes to your treatment plan.
- PubMed, peer-reviewed research article, 'Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents,' EBioMedicine, date not specified in source material.